Preclinical Study Shows Reduction in Disease Severity
• Cellmid has recently completed in vivo testing of two of its anti-midkine antibodies
• Both antibodies decreased disease severity in an animal model of multiple sclerosis
• Key mechanisms of actions have been demonstrated
Cellmid and Pacific Edge Sign Cancer Diagnostic License
Sydney, 19 May 2010 - Cellmid Limited (ASX:CDY) and Pacific Edge Biotechnology Limited (PEB), have entered into a non-exclusive license agreement for the use of CDY’s midkine technology in PEB’s bladder cancer test.
Cellmid will receive upfront and milestone payments in addition to royalties on product sales.